Factors responsible for long-term survival in metastatic breast cancer

World Journal of Surgical Oncology

Volumn 12, Issue 1, 2014, Pages

  Kontani, Keiichi ^a   Hashimoto, Shin Ichiro ^a   Murazawa, Chisa ^a   Norimura, Shoko ^b   Tanaka, Hiroaki ^c   Ohtani, Masahiro ^d   Fujiwara Honjo, Naomi ^e   Date, Manabu ^f   Teramoto, Koji ^g   Houchi, Hitoshi ^c   Yokomise, Hiroyasu ^a  

^a KAGAWA UNIVERSITY   (Japan)

^b TAKAMATSU RED CROSS HOSPITAL   (Japan)

^c KAGAWA UNIVERSITY HOSPITAL   (Japan)

^d Kagawa Health Service Association   (Japan)

^e Osaka Neurosurgery Hospital   (Japan)

^f National Hospital Organization   (Japan)

^g SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

Long term survival; Metastatic breast cancer; Metronomic chemotherapy; Prognostic factor

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB;

ADULT; AGED; ARTICLE; BREAST METASTASIS; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; HUMAN; LONG TERM SURVIVAL; MAJOR CLINICAL STUDY; MASTECTOMY; METASTATIC BREAST CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; RETROSPECTIVE STUDY; TREATMENT FAILURE; TRIPLE NEGATIVE BREAST CANCER; VERY ELDERLY; BREAST NEOPLASMS; CANCER GRADING; CANCER STAGING; FEMALE; FOLLOW UP; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; TIME; TUMOR INVASION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS;

EID: 84920816121     PISSN: None     EISSN: 14777819     Source Type: Journal    
DOI: 10.1186/1477-7819-12-344     Document Type: Article

References (39)

1. Yamamoto N, Tada K, Hori H: Improvement in the prognosis of Japanese breast cancer from 1946 to 2001-An institutional reviews. Jpn J Clin Oncol 2004, 34:1-6.
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG): Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005, 365:1687-1717.
3. Greenberg PA, Hortbagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU: Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996, 14:2197-2205.
4. Rahman ZU, Frye DK, Smith TL, Asmar L, Theriault LA, Buzdar AU, Hortbagyi GN: Results and long term follow-up for 1581 patients with metastatic breast carcinoma treated with standard dose doxorubicin-containing chemotherapy: a reference. Cancer 1999, 85:104-111.
5. Schneeweiss A, Hensel M, Sinn P, Khbeis T, Haas R, Bastert G, Ho AD: Characteristics associated with long-term progression-free survival following high-dose chemotherapy in metastatic breast cancer and influence of chemotherapy dose. Ann Oncol 2002, 13:679-688.
6. Jassem J, Pienkowski T, Pluzanska A, Jelic S, Gorbunova V, Mrsic-Krmpotic Z, Berzins J, Nagykalnai T, Wigler N, Renard J, Munier S, Weil C: Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J Clin Oncol 2001, 19:1707-1715.
7. Perez DJ, Harvey VJ, Robinson BA, Atkinson CH, Dady PJ, Kirk AR, Evans BD, Chapman PJ: A randomized comparison of single-agent doxorubicin and epirubicin as first-line cytotoxic therapy in advanced breast cancer. J Clin Oncol 1991, 9:2148-2152.
8. Bonneterre J, Dieras V, Tubiana-Hulin M, Bougnoux P, Bonneterre ME, Delozier T, Mayer F, Culine S, Dohoulou N, Bendahmane B: Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer. Br J Cancer 2004, 91:1466-1471.
9. Sledge GW, Neuberg D, Bernardo P, Ingle JN, Martino S, Rowinsky EK, Wood WC: Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193). J Clin Oncol 2003, 21:588-592.
10. Paridaens R, Biganzoli L, Bruning P, Klijn JG, Gamucci T, Houston S, Coleman R, Schachter J, Van Vreckem A, Sylvester R, Awada A, Wildiers J, Piccart M: Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over. J Clin Oncol 2000, 18:724-733.
11. Chan S, Friedrichs K, Noel D, Pintér T, Van Belle S, Vorobiof D, Duarte R, Gil Gil M, Bodrogi I, Murray E, Yelle L, von Minckwitz G, Korec S, Simmonds P, Buzzi F, González Mancha R, Richardson G, Walpole E, Ronzoni M, Murawsky M, Alakl M, Riva A, Crown J: Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1999, 17:2341-2354.
12. Bontenbal M, Andersson M, Wildiers J, Cocconi G, Jassem J, Paridaens R, Rotmensz N, Sylvester R, Mouridsen HT, Klijn JG, van Oosterom AT: Doxorubicin vs epirubicin, report of a second-line randomized phase II/III study in advanced breast cancer. EORTC Breast Cancer Cooperative Group. Br J Cancer 1998, 77:2257-2263.
13. Rha SY, Moon YH, Jeung HC, Kim YT, Sohn JH, Yang WI, Suh CO, Kim GE, Roh JK, Chung HC: Gemcitabine monotherapy as salvage chemotherapy in heavily pretreated metastatic breast cancer. Breast Cancer Res Treat 2005, 90:215-221.
14. Spielmann M, Llombart-Cussac A, Kalla S, Espié M, Namer M, Ferrero JM, Diéras V, Fumoleau P, Cuvier C, Perrocheau G, Ponzio A, Kayitalire L, Pouillart P: Single-agent gemcitabine is active in previously treated metastatic breast cancer. Oncology 2001, 60:303-307.
15. Zelek L, Barthier S, Riofrio M, Fizazi K, Rixe O, Delord JP, Le Cesne A, Spielmann M: Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma. Cancer 2001, 92:2267-2272.
16. Gasparini G, Caffo O, Barni S, Frontini L, Testolin A, Guglielmi RB, Ambrosini G: Vinorelbine is an active antiproliferative agent in pretreated advanced breast cancer patients: a phase II study. J Clin Oncol 1994, 12:2094-2101.
17. Blum JL, Dieras V, Lo Russo PM, Horton J, Rutman O, Buzdar A, Osterwalder B: Multicenter, Phase II study of capecitabine in taxane-pretreated metastatic breast carcinoma patients. Cancer 2001, 92:1759-1768.
18. Blum JL, Jones SE, Buzdar AU, LoRusso PM, Kuter I, Vogel C, Osterwalder B, Burger HU, Brown CS, Griffin T: Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol 1999, 17:485-493.
19. Jassem J, Carroll C, Ward SE, Simpson E, Hind D: The clinical efficacy of cytotoxic agents in locally advanced or metastatic breast cancer patients pretreated with an anthracycline and a taxane: a systematic review. Eur J Cancer 2009, 45:2749-2758.
20. Amoroso V, Valcamonico F, Simoncini E, Ardighieri L, Grisanti S, Vassalli L, Marpicati P, Lucini L, Ferrari VD, Rangoni G, Marini G: A retrospective series of long-term survivors of metastatic breast cancer in complete remission. Oncology 2005, 68:48-51.
21. Yamamoto N, Katsumata N, Watanabe T, Omuro Y, Ando M, Narabayashi M, Adachi I: Clinical characteristics of patients with metastatic breast cancer with complete remission following systemic treatment. Jpn J Clin Oncol 1998, 28:368-373.
22. Therasse P, Arbuck SG, Eisenhauer EA, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors: European Organisation for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Unstitute of Canada. J Natl Cancer Inst 2000, 92:205-216.
23. National Cancer Institute: Commom Terminology Criteria for Adverse Events (CTCAE), version 3.0 published August 9, 2006. http://ctep.cancer. gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf.
24. Brookmeyer R, Crowley J: A Confidence Interval for the Median Survival Time. Biometrics 1982, 38:29-41.
25. Smith I, Chua S: Medical treatment of early breast cancer. I. Adjuvant treatment. BMJ 2006, 332:34-37.
26. Bria E, Nistico C, Cuppone F, Carlini P, Ciccarese M, Milella M, Natoli G, Terzoli E, Cognetti F, Giannarelli D: Benefit of taxanes as adjuvant chemotherapy for early breast cancer: Pooled analysis of 15,500 patients. Cancer 2006, 106:2337-2344.
27. Buzdar AU, Singletary SE, Valero V, Booser DJ, Ibrahim NK, Rahman Z, Theriault RL, Walters R, Rivera E, Smith TL, Holmes FA, Hoy E, Frye DK, Manuel N, Kau SW, McNeese MD, Strom E, Thomas E, Hunt K, Ames F, Berry D, Hortobagyi GN: Evaluation of paclitaxel in adjuvant chemotherapy for patients with operable breast cancer: preliminary data of a prospective randomized trial. Clin Cancer Res 2002, 8:1073-1079.
28. O'Shaughnessy J, Miles D, Vukelja S, Moiseyenko V, Ayoub JP, Cervantes G, Fumoleau P, Jones S, Lui WY, Mauriac L, Twelves C, Van Hazel G, Verma S, Leonard R: Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002, 20:2812-2823.
29. Albain KS, Nag SM, Calderillo-Ruiz G, Jordaan JP, Llombart AC, Pluzanska A, Rolski J, Melemed AS, Reyes-Vidal JM, Sekhon JS, Simms L, O'Shaughnessy J: Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol 2009, 26:3950-3957.
30. Nielsen DL, Bjerre KCD, Jakobsen EH, Cold S, Stenbygaard L, Sørensen PG, Kamby C, Møller S, Jørgensen CLT, Andersson M: Gemcitabine plus docetaxel versus docetaxel in patients with predominantly human epidermal growth factor receptor 2-negative locally advanced or metastatic breast cancer. J Clin Oncol 2011, 29:4748-4754.
31. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D, Davidson NE: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007, 357:2666-2676.
32. Brufsky AM, Hurvitz S, Perez E, Swamy R, Valero V, O'Neill V, Rugo HS: RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2011, 29:4286-4293.
33. Robert NJ, Diéras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, Perez EA, Yardley DA, Chan SY, Zhou X, Phan SC, O'Shaughnessy J: RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2009, 29:1252-1260.
34. Kontani K, Hashimoto S, Murazawa C, Norimura S, Tanaka H, Ohtani M, Fujiwara-Honjo N, Date M, Houchi H, Yokomise H, Yamauchi A: Metronomic chemotherapy for metastatic breast cancer to prolong time to treatment failure to 12 months or more. Mol Clin Oncol 2013, 1:225-230.
35. Oostendorp LJ, Stalmeier PF, Donders AR, van der Graaf WT, Ottevanger PB: Efficacy and safety of palliative chemotherapy for patients with advanced breast cancer pretreated with anthracyclines and taxanes: a systematic review. Lancet Oncol 2011, 12:1053-1061.
36. Kerbel RS, Kamen BA: The anti-angiogenic basis of metronomic chemotherapy. Nat Rev Cancer 2004, 4:423-436.
37. Colleoni M, Rocca A, Sandri MT, Zorzino L, Masci G, Nolè F, Peruzzotti G, Robertson C, Orlando L, Cinieri S, de BF, Viale G, Goldhirsch A: Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol 2002, 13:73-80.
38. Colleoni M, Orlando L, Sanna G, Rocca A, Maisonneuve P, Peruzzotti G, Ghisini R, Sandri MT, Zorzino L, Nolè F, Viale G, Goldhirsch A: Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. Ann Oncol 2006, 17:232-238.
39. Wong NS, Buckman RA, Clemons M, Verma S, Dent S, Trudeau ME, Roche K, Ebos J, Kerbel R, Deboer GE, Sutherland DJ, Emmenegger U, Slingerland J, Gardner S, Pritchard KI: Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response. J Clin Oncol 2010, 28:723-730.